Quiescent cells repress cell-cycle genes via chromatin-based mechanisms to maintain a non-dividing state, yet remain poised to reenter the cell cycle upon stimulation. E2F1, a canonical activator of cell-cycle genes, is sufficient to induce cell-cycle reentry from quiescence, but how it overcomes chromatin-mediated rep...
G. A. Lodewijk, Benjamin R. Topacio, Seung-Ho Lee et al.· EMBO Journal· 0 citations
LDDM (Large Drug Discovery Model) is introduced, a generative framework that supports a range of drug discovery tasks, including constrained and unconstrained docking, fragment linking and growing, and de novo design, and a programmable design algorithm that enables accurate design of synthetically accessible compounds...
Ilia Igashov, Arne Schneuing, Adrian W. Dobbelstein et al.· bioRxiv· 0 citations
This pipeline identified 6 known and 43 novel CRBN-pomalidomide binders, including orthogonally validated hits that provide privileged starting points for MGD development, and expects this binding-focused workflow to be applicable to other MGD-E3 ligase systems, potentially extending the scope of this emerging drug cla...
Pius Galli, Shuhao Xiao, Y. Meng et al.· Nature Biotechnology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.